Guiding Management of Bethesda V Thyroid Nodules: The Role of Molecular Testing.

Clin Endocrinol (Oxf) · 2026 · PMC12669814 · PMID 40964868

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

did not reach statistical significancep = 0.06so close (0.05 < p ≤ 0.1)

In contrast, the low‐risk group ( n = 49) displayed a more balanced distribution, with ThyGenext utilized in 63.3% of cases and Thyroseq in 36.7%, though the difference did not reach statistical significance ( p = 0.06). 3.3.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.